The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.1% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224.
AstraZeneca PLC
AZN · NASDAQ (ADR) · Market cap $260.7B · 96,100 employees
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Not yet scoredPrice as of 19 Nov 2026Daily close, not a live quote
Screened 2026-11-19 · the tape above runs as of 12:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price175.41 at the 19 Nov 2026 close
- Our value readFair vs our fair value, as of 19 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans heavily to calls (put/call 0.59)
- Last reviewed19 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: 161.69 to 185.94 , base estimate 161.69 (screen dated 2026-11-19).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.59, read 2026-11-19
- Ethical screen not yet scored
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
AstraZeneca PLC holds its Markup at $175.41. Consolidating, no directional conviction, held for 10 days.
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 10 days |
| Price at the screen | $175.41 |
| Valuation | 27.40 trailing · 28.48 forward price to earnings |
| Values screen | Not scored · score 50.0 |
| Beta | 0.22 |
Five Screens: AZN's Results
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Revenue purity | 0.61% | Below 5% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadThe Read, in Plain English
AstraZeneca clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-19. It updates when the underlying figures move, and past reads are kept below.
What the Numbers Say It Is WorthThe Fair Value Range
Our analysis reads Fair vs our fair value, as of 19 Nov 2026: it trades above our 161.69 fair value estimate, moderate competitive moat, 12.50% revenue growth.
Model construction and limits: fair-value methodology.
Fair value range in , drawn from the 2026-11-19 screen. The gold marker is the market price at the same screen. The price runs 8.5% above the base estimate.
Third-party analyst targets: 10 covering, consensus Strong Buy. The average target sits +28% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere our models see it going: fair-value estimate 161.69 , with a range of 161.69 to 185.94 , dated to the 2026-11-19 screen.
How our estimate and third-party targets differ.
The Business, in Plain Words| Forward P/E | 28.5xexpensive even after accounting for its growth |
| Trailing P/E | 27.4xa premium valuation |
| EPS, forward | 5.90 |
| Revenue growth | +12.5%steady growth |
| Profit margin | 17.2%healthy profit margins |
| Return on equity | 23.5%an exceptional return on shareholder capital |
| Dividend yield | 1.76% |
| Debt to equity | 0.72moderate, manageable leverage |
| Current ratio | 0.91below 1: short-term bills exceed liquid assets |
| Beta | 0.22barely tracks the market's swings |
| Short interest, float | 0.00% |
| 52-week range | 136.16 - 212.71 |
| Moat | MODERATE |
| Market cap | $260.7B |
| Employees | 96,100 |
AZN-specific watchpoints · The things to watch: its business and earnings are exposed to United Kingdom and to currency swings; as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.1% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224.
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224.
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224.
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 9.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224. It reported earnings in this window, a natural checkpoint for the thesis.
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical pass with moderate score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 4% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 23%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (10 analysts) rates it strong buy, with a mean price target of $224. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-14 | Soriot (Pascal) | 18,359 | · | ||
| 2026-03-05 | Soriot (Pascal) | 101,495 | · | ||
| 2026-03-04 | Soriot (Pascal) | 14,967 | · | ||
| 2026-03-04 | Sarin (Aradhana M.D.) | 4,863 | · | ||
| 2026-01-31 | Investor AB | · | · | ||
| 2026-01-31 | BlackRock Financial Management, Inc. | · | · | ||
| 2026-01-31 | The Capital Group Companies, Inc. | · | · | ||
| 2026-01-31 | Wellington Management Company, L.L.P. | · | · | ||
| 2025-12-31 | Wallenberg (Marcus) | · | · | ||
| 2025-12-31 | Wellington Management Company, L.L.P. | · | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $181.86 | -2.0% | · | $980 | -2.0% |
| 2 months | $204.03 | -12.6% | · | $874 | -12.6% |
| 3 months | $192.50 | -7.4% | · | $926 | -7.4% |
| 6 months | $178.72 | -0.3% | $2.15 | $1,010 | +1.0% |
| 1 year | $145.13 | +22.8% | $3.18 | $1,250 | +25.0% |
| 2 years | $154.50 | +15.4% | $6.28 | $1,195 | +19.5% |
| 3 years | $139.58 | +27.7% | $9.18 | $1,343 | +34.3% |
| 5 years | $105.80 | +68.5% | $14.95 | $1,826 | +82.6% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever AZN does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.